Brainlab, a Germany-based global medtech company has spun-off the Snke Group. Snke, led by Stefan Vilsmeier, acts as an orchestration layer that connects data points from various stakeholders, products and services. In this way, it bridges the traditionally separate domains of medical devices and hospital IT.
Snke delivers next-generation products and services that tightly integrate medical research, education and treatment. The strategic realignment of Brainlab’s portfolio creates a more focused direction for the firm to pursue its growth strategy. It also creates an independent player in the healthtech space, allowing Snke to focus on expanding market access and driving greater adoption of its technology through increased industry collaboration.
“Snke is ready to enter and disrupt the market,” said Stefan Vilsmeier, CEO of Snke and chairman of the Supervisory Board at Brainlab. “In this next chapter Snke aims to accelerate its long-term evolution into a leading IT infrastructure provider for hospitals. As both companies have very different risk profiles and business models, this step enables Brainlab, at the same time, to redirect its full focus and means to further driving profitable growth.”
In January 2025, after founding and leading Brainlab for 35 years, Vilsmeier transitioned to chairman of the Supervisory Board. Rainer Birkenbach, who has worked closely with Vilsmeier since 1994, has taken on the role of CEO at Brainlab.
IPO
The spin-off occurred prior to the commencement of a bookbuilding process for Brainlab’s IPO. Brainlab is looking to raise up to €200m from the sale of 2 million new shares at a price between €80m and €100m. It will also sell up to 3.2 million secondary shares held by entities of EMH, SV2019, an investment vehicle of Stefan Vilsmeier and BMB Verwaltungsgesellschaft.
With all shares placed, market capitalization of Brainlab would be between around €1.67bn and €2.09bn. Press release: Brainlab Announces Spin-off of Snke | Brainlab
